CORDIS
EU research results

CORDIS

English EN
Computational ONcology TRaining Alliance

Computational ONcology TRaining Alliance

Objective

Cancer is a major cause of death and suffering, rendering it a huge concern to the general public. Consequently, it has been targeted by application of the molecular techniques developed during the last 20-25 years, thereby improving diagnosis and treatment. Nevertheless, although current biomarker and treatment concepts often are successful initially, they subsequently frequently fail to achieve durable drug response and long-term survival for cancer patients. The study of somatic evolution in cancer is a very promising approach to rectify this situation. Fortunately, single cell genomic sequencing has recently begun to provide opportunity to unprecedented detailed insights into tumour evolution and new techniques are emerging for assaying the spatial distribution of tumour heterogeneity. Analysing and developing methods for these emerging data sets are under-researched areas that lie at the intersection of medical, evolutionary biology, and computational research. In CONTRA, European researchers with complementary expertise have joined forces in order to collectively facilitate training of future European computational cancer researchers. We will by applying modern recruitment and selection methods in combination with offering excellent training and employments conditions, including social security, facilitate recruitment of 15 excellent ESRs, across genders and geographical areas. We will train these 15 ESRs in the mathematical, computational, and applied skills required to tackle the complex analysis problems posed by somatic evolution in cancer. We will also teach them entrepreneurship and the requirements of pharmaceutical and biotech industry. Using a novel scheme, this substantial academic cancer expertise will be complemented with industrial expertise in software development, especially for biotech and pharmaceutical industry, which will unleash key components of the innovative force of the European commercial sector in the struggle against cancer.

Coordinator

KUNGLIGA TEKNISKA HOEGSKOLAN

Address

Brinellvagen 8
100 44 Stockholm

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 527 318,64

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)

Spain

EU Contribution

€ 495 745,92

UNIVERSIDAD DE VIGO

Spain

EU Contribution

€ 495 745,92

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 546 575,76

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 546 575,76

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

Switzerland

EU Contribution

€ 530 453,52

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

United Kingdom

EU Contribution

€ 273 287,88

UNIWERSYTET WARSZAWSKI

Poland

EU Contribution

€ 448 274,88

Partners (7)

Sort alphabetically

Expand all

Ardigen SA

Merck KGaA

TORUS SOFTWARE SOLUTIONS S.L.

FUNDACION CENTRO TECNOLOXICO DE TELECOMUNICACIONS DE GALICIA

Spatial Transcriptomics AB

Seven Bridges Genomics UK Limited

British Columbia Cancer Agency Branch

Project information

Grant agreement ID: 766030

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    31 December 2021

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 863 978,28

  • EU contribution

    € 3 863 978,28

Coordinated by:

KUNGLIGA TEKNISKA HOEGSKOLAN

Sweden